An Insight Into the Interaction of Oxo-Vanadium (V) Complex with Nucleic acid

Vanadium complex show protective effects against chemical carcinogenesis on animals, by altering, mainly, various xenobiotic enzymes, inhibiting, thus, carcinogen-derived active metabolites. Studies on various cell lines reveal that vanadium exerts its antitumor effects through inhibition of cellular tyrosine phosphatases and/or activation of tyrosine phosphorylases. It also possesses low toxicity. In combination with the synthesis of new, more potent and better tolerated complexes, these are reported as an effective non-platinum, metal antitumor agent. N-Aryl hydroxamic acids (RC (=O)N(OH)R?) as a chelating agents form highly stable complex with Vanadium(V). The binding parameters of Vanadium(V) complex of the parent compound of this series, i.e., N-Phenylbenzohydroxamic acid (PBHA) complex using calf thymus DNA (ct-DNA) and torula yeast RNA (t-RNA) have been determined and reported first time following the UV, fluorescence and viscometric techniques. The complex shows the ability of cooperatively minor groove binding with ctDNA as indicated by remarkable hyperchromicity and blue shift of the absorption spectra. Quenching of metal complex calculation was carried out with Stern-Volmer equation and Ksv was found to be 2.32?0.18?104 M -1 , while in case of t-RNA enhancement is observed that means compound was not able to displace ethidiumbromide (EB)-t-RNA complex. Molecular docking was also applied, result complements and predicted as minor groove as the mode of interaction of the hydroxamic acid with ct-DNA and t-RNA.